close

Press release

SRI International awarded $40 million NICHD contract for pre-clinical development of new male and female contraceptive products

Under the contract, SRI is responsible for all preclinical support services necessary to progress toward the development of high-quality, safe and effective male and female contraceptive products

...global health goals,” said Toufan Parman, senior director of toxicology and immunology, SRI International, and the principal investigator for the NICHD contract. “We are honored to have been selected for...

Article October 20, 2020

Serum Biomarkers Reveal Long-term Cardiac Injury in Isoproterenol-treated African Green Monkeys

The assessment of cardiac toxicity is a major challenge in both drug development and clinical trials, and numerous marketed pharmaceuticals have been removed from the market due to unpredicted cardiac effects. Serum troponins are widely used indicators of cardiac injury;…

Article October 20, 2020

Safety and Pharmacokinetic of Single Dose Novel Oral Androgen 11β-Methyl-19-Nortestosterone-17β-dodecylcarbonate in Men

Context: 11β-Methyl-19-nortestosterone-17β-dodecylcarbonate (11β-MNTDC) is an orally bioavailable prodrug of 11β-methyl-19-nortestosterone (11β-MNT) with androgenic and progestational activity. Objectives: (i) Quantify 11β-MNT binding to androgen and progesterone receptors. (ii) Evaluate safety, tolerability, and serum gonadotropin and testosterone suppression by 11β-MNTDC in men.…

Article May 21, 2019

Increased stress associated with head-out plethysmography testing can exacerbate respiratory effects and lead to mortality in rats

Introduction: DSM421, a dihydroorotate dehydrogenase inhibitor, was in preclinical development as a potential treatment option for malaria. When tested in a core battery of safety pharmacology assays, DSM421 did not produce any effects at oral doses up to 750 mg/kg in…

Article June 1, 2015

Characterization of Batracylin-Induced Renal and Bladder Toxicity in Rats

Batracylin (NSC-320846) is a dual inhibitor of DNA topoisomerases I and II. Batracylin advanced as an anticancer agent to Phase I clinical trials where dose limiting hemorrhagic cystitis (bladder inflammation...

Article December 1, 2014

Quantitative Proteomics for Cardiac Biomarker Discovery Using Isoproterenol-Treated Nonhuman Primates

Abstract To identify new cardiac biomarkers, a quantitative proteomic analysis has been performed on serum and heart tissue proteins from three species of nonhuman primates following isoproterenol (ISO) treatment. Three...

Article December 1, 2014

Comparative Uterotrophic Effects of Endoxifen and Tamoxifen in Ovariectomized Sprague-Dawley Rats

Endoxifen (4-hydroxy-N-desmethyl-tamoxifen), one of the major active metabolites of tamoxifen, has substantially greater estrogen antagonist properties and antiproliferative effects in breast tumor cells than tamoxifen, a mixed estrogen agonist/antagonist. An...

Conference Paper June 1, 2013

Non-Clinical Safety Evaluation of Xoma 3AB, a Novel Triple Antibody Drug Product Targeting Botulinum Toxin Type a, in Sprague-Dawley Rats

Article March 1, 2013

Serum Biomarkers Reveal Long-Term Cardiac Injury in Isoproterenol-Treated African Green Monkeys

The assessment of cardiac toxicity is a major challenge in both drug development and clinical trials, and numerous marketed pharmaceuticals have been removed from the market due to unpredicted cardiac...

Conference Paper March 1, 2013

Assessment of Cardiac Biomarkers in Cynomolgus Macaques

Journal Article August 1, 2012

Identification of (+)-Erythro-Mefloquine as an Active Enantiomer with Greater Efficacy than Mefloquine Against Mycobacterium Avium Infection in Mice

Journal Article June 1, 2012

Lead Optimization of Antimalarial Propafenone Analogues

close check icon

Message Sent

Success! - Thank you for your interest.

share dwonload plus email external external project copy play call directions linkedin